You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma

 

Online download statistics by month:

Online download statistics by month: November 2020 to September 2024

AbstractFullPdf
Nov 2020139020
Dec 202052010
Jan 20217009
Feb 20216407
Mar 202174013
Apr 20216205
May 20216307
Jun 2021007
Jul 20210011
Aug 2021008
Sep 20210010
Oct 202182028
Nov 202176013
Dec 20212803
Jan 20222806
Feb 20222405
Mar 20223007
Apr 20228205
May 20224404
Jun 20227205
Jul 20225405
Aug 20224205
Sep 20224405
Oct 20224801
Nov 20225002
Dec 20226404
Jan 20234200
Feb 20233401
Mar 20234604
Apr 20232602
May 20233403
Jun 20231600
Jul 20232003
Aug 20232302
Sep 20231800
Oct 20233003
Nov 20232803
Dec 20236200
Jan 20247200
Feb 20245402
Mar 20243001
Apr 20243405
May 20244001
Jun 20243604
Jul 20243202
Aug 20245002
Sep 20246003
Total20790246